Abbott Declares 410th Consecutive Quarterly Dividend
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: PRnewswire
- Quarterly Dividend Declaration: Abbott's board has declared a quarterly common dividend of 63 cents per share, marking the 410th consecutive quarterly dividend since 1924, demonstrating the company's robust cash flow and profitability.
- Consistent Dividend Growth: Abbott has increased its dividend payout for 54 consecutive years, making it a member of the S&P 500 Dividend Aristocrats Index, reflecting the company's long-term commitment to shareholder returns and financial health.
- Dividend Payment Timing: The cash dividend will be payable on August 17, 2026, to shareholders of record as of July 15, 2026, ensuring timely returns for investors and enhancing confidence in the stock.
- Global Healthcare Leader: Abbott is a global leader in healthcare with a diverse portfolio spanning diagnostics, medical devices, nutritionals, and branded generic medicines, dedicated to improving quality of life and further solidifying its market position.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABT
Wall Street analysts forecast ABT stock price to rise
19 Analyst Rating
17 Buy
2 Hold
0 Sell
Strong Buy
Current: 89.650
Low
136.00
Averages
148.11
High
169.00
Current: 89.650
Low
136.00
Averages
148.11
High
169.00
About ABT
Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Abbott Declares 410th Consecutive Quarterly Dividend
- Quarterly Dividend Declaration: Abbott's board has declared a quarterly common dividend of 63 cents per share, marking the 410th consecutive quarterly dividend since 1924, demonstrating the company's robust cash flow and profitability.
- Consistent Dividend Growth: Abbott has increased its dividend payout for 54 consecutive years, making it a member of the S&P 500 Dividend Aristocrats Index, reflecting the company's long-term commitment to shareholder returns and financial health.
- Dividend Payment Timing: The cash dividend will be payable on August 17, 2026, to shareholders of record as of July 15, 2026, ensuring timely returns for investors and enhancing confidence in the stock.
- Global Healthcare Leader: Abbott is a global leader in healthcare with a diverse portfolio spanning diagnostics, medical devices, nutritionals, and branded generic medicines, dedicated to improving quality of life and further solidifying its market position.
See More
Abbott Declares 410th Consecutive Quarterly Dividend
- Dividend Declaration: Abbott's board announced a quarterly dividend of 63 cents per share, marking the 410th consecutive quarterly dividend since 1924, demonstrating the company's ongoing commitment to shareholder returns.
- Historical Achievement: Abbott has increased its dividend for 54 consecutive years, making it a member of the S&P 500 Dividend Aristocrats Index, reflecting its stable profitability and strong cash flow management.
- Payment Timeline: The cash dividend will be payable on August 17, 2026, to shareholders of record as of July 15, 2026, ensuring timely returns for investors and enhancing their confidence in the company.
- Global Impact: As a global healthcare leader, Abbott's dividend policy not only attracts investors but also strengthens its market position in over 160 countries, driving the company's long-term sustainable growth.
See More
Elfun Trusts Q1 2026 Investment Moves Revealed
- Portfolio Adjustment: Elfun Trusts exited three stocks in Q1 2026, notably selling all 707,792 shares of Abbott Laboratories, which impacted the portfolio by -1.97%, indicating a cautious stance towards the healthcare sector.
- New Stock Additions: The fund added 1,148,700 shares of Boston Scientific, valued at approximately $72.08 million, representing 1.75% of the portfolio, reflecting optimism in the medical device industry.
- Key Position Increases: Elfun Trusts increased its stake in S&P Global by 47,560 shares, bringing total holdings to 222,549 shares, a 27.18% increase, demonstrating confidence in financial information services.
- Reduction Strategy: The fund reduced positions in 18 stocks, notably cutting 169,600 shares of Emerson Electric, a 25.49% decrease, reflecting a reassessment of the industry's outlook.
See More
Three Ideal Stocks for New Investors
- Visa Financial Performance: Visa reported a profit of $22 billion and revenue of $43 billion over the past 12 months, achieving an impressive profit margin of 51%, highlighting its strong profitability in the global payments market, making it suitable for long-term investors.
- Home Depot's Resilience: Despite challenges from a slowing housing market, Home Depot generated $167 billion in revenue and $14 billion in profit over the past four quarters, with a profit margin of about 8% and a dividend yield of 2.99%, appealing to buy-and-hold investors.
- Abbott's Diversified Revenue: Abbott Laboratories achieved $45 billion in sales and approximately $6.3 billion in profit over the past 12 months, resulting in a net margin of around 14%, and its diversified business model offers investors stable growth potential.
- Dividend Appeal: Abbott's dividend yield stands at 2.8%, and it has consistently raised its payout for over 50 years, earning the title of 'Dividend King', making it a compelling long-term investment choice.
See More
Beyond Meat's Strategic Shift to Protein Drinks Amid Financial Struggles
- Sales Decline: Beyond Meat reported a net revenue of $275 million in 2025, reflecting a 16% year-over-year drop, indicating waning consumer interest in its plant-based meat products, which has severely impacted market confidence and investor sentiment.
- Increased Operating Losses: The company's operating losses surged to $333 million in 2025, more than doubling from 2024, as the cost of goods sold nearly matched revenue, highlighting ongoing profitability challenges that necessitated a strategic pivot.
- New Product Launch: In response to these challenges, Beyond Meat launched its Beyond Immerse protein drink line in January 2026, entering a $35 billion market projected to grow at a 9.4% CAGR; however, the company's lack of commitment to this product line raises doubts about its potential to regain investor confidence.
- Poor Financial Performance: In Q1 2026, Beyond Meat's net revenue fell to $58 million, down 15% year-over-year, and while losses improved, the absence of any signs of financial recovery suggests that investors should remain cautious about the company's future performance.
See More
Beyond Meat Launches Limited-Time Protein Drink Line
- Market Challenges: According to research data, the protein drink industry is growing at high single-digit levels, while Beyond Meat's net revenue fell to $275 million in 2025, down 16% year-over-year, indicating a decline in consumer interest in its plant-based meat products and resulting in severe financial challenges for the company.
- Product Launch: Beyond Meat launched its Beyond Immerse line of protein drinks in January 2026, and although the market is projected to reach $35 billion with a 9.4% CAGR through 2032, the product's limited-time offering has failed to boost investor confidence significantly.
- Deteriorating Financials: In Q1 2026, Beyond Meat reported net revenue of $58 million, a 15% year-over-year decline, and while losses improved from $61 million to $28 million, the company has yet to show signs of financial recovery, reflecting its vulnerable position in a competitive beverage market.
- Bleak Investment Outlook: Competing against industry giants like PepsiCo and Coca-Cola, Beyond Meat's protein drinks have not proven to be the turnaround catalyst needed for its stock, leading investors to approach the stock with caution unless the products gain traction and demonstrate sales growth.
See More
Abbott Declares 410th Consecutive Quarterly Dividend
- Quarterly Dividend Declaration: Abbott's board has declared a quarterly common dividend of 63 cents per share, marking the 410th consecutive quarterly dividend since 1924, demonstrating the company's robust cash flow and profitability.
- Consistent Dividend Growth: Abbott has increased its dividend payout for 54 consecutive years, making it a member of the S&P 500 Dividend Aristocrats Index, reflecting the company's long-term commitment to shareholder returns and financial health.
- Dividend Payment Timing: The cash dividend will be payable on August 17, 2026, to shareholders of record as of July 15, 2026, ensuring timely returns for investors and enhancing confidence in the stock.
- Global Healthcare Leader: Abbott is a global leader in healthcare with a diverse portfolio spanning diagnostics, medical devices, nutritionals, and branded generic medicines, dedicated to improving quality of life and further solidifying its market position.
See More
Abbott Declares 410th Consecutive Quarterly Dividend
- Dividend Declaration: Abbott's board announced a quarterly dividend of 63 cents per share, marking the 410th consecutive quarterly dividend since 1924, demonstrating the company's ongoing commitment to shareholder returns.
- Historical Achievement: Abbott has increased its dividend for 54 consecutive years, making it a member of the S&P 500 Dividend Aristocrats Index, reflecting its stable profitability and strong cash flow management.
- Payment Timeline: The cash dividend will be payable on August 17, 2026, to shareholders of record as of July 15, 2026, ensuring timely returns for investors and enhancing their confidence in the company.
- Global Impact: As a global healthcare leader, Abbott's dividend policy not only attracts investors but also strengthens its market position in over 160 countries, driving the company's long-term sustainable growth.
See More
Elfun Trusts Q1 2026 Investment Moves Revealed
- Portfolio Adjustment: Elfun Trusts exited three stocks in Q1 2026, notably selling all 707,792 shares of Abbott Laboratories, which impacted the portfolio by -1.97%, indicating a cautious stance towards the healthcare sector.
- New Stock Additions: The fund added 1,148,700 shares of Boston Scientific, valued at approximately $72.08 million, representing 1.75% of the portfolio, reflecting optimism in the medical device industry.
- Key Position Increases: Elfun Trusts increased its stake in S&P Global by 47,560 shares, bringing total holdings to 222,549 shares, a 27.18% increase, demonstrating confidence in financial information services.
- Reduction Strategy: The fund reduced positions in 18 stocks, notably cutting 169,600 shares of Emerson Electric, a 25.49% decrease, reflecting a reassessment of the industry's outlook.
See More
Three Ideal Stocks for New Investors
- Visa Financial Performance: Visa reported a profit of $22 billion and revenue of $43 billion over the past 12 months, achieving an impressive profit margin of 51%, highlighting its strong profitability in the global payments market, making it suitable for long-term investors.
- Home Depot's Resilience: Despite challenges from a slowing housing market, Home Depot generated $167 billion in revenue and $14 billion in profit over the past four quarters, with a profit margin of about 8% and a dividend yield of 2.99%, appealing to buy-and-hold investors.
- Abbott's Diversified Revenue: Abbott Laboratories achieved $45 billion in sales and approximately $6.3 billion in profit over the past 12 months, resulting in a net margin of around 14%, and its diversified business model offers investors stable growth potential.
- Dividend Appeal: Abbott's dividend yield stands at 2.8%, and it has consistently raised its payout for over 50 years, earning the title of 'Dividend King', making it a compelling long-term investment choice.
See More
Beyond Meat's Strategic Shift to Protein Drinks Amid Financial Struggles
- Sales Decline: Beyond Meat reported a net revenue of $275 million in 2025, reflecting a 16% year-over-year drop, indicating waning consumer interest in its plant-based meat products, which has severely impacted market confidence and investor sentiment.
- Increased Operating Losses: The company's operating losses surged to $333 million in 2025, more than doubling from 2024, as the cost of goods sold nearly matched revenue, highlighting ongoing profitability challenges that necessitated a strategic pivot.
- New Product Launch: In response to these challenges, Beyond Meat launched its Beyond Immerse protein drink line in January 2026, entering a $35 billion market projected to grow at a 9.4% CAGR; however, the company's lack of commitment to this product line raises doubts about its potential to regain investor confidence.
- Poor Financial Performance: In Q1 2026, Beyond Meat's net revenue fell to $58 million, down 15% year-over-year, and while losses improved, the absence of any signs of financial recovery suggests that investors should remain cautious about the company's future performance.
See More
Beyond Meat Launches Limited-Time Protein Drink Line
- Market Challenges: According to research data, the protein drink industry is growing at high single-digit levels, while Beyond Meat's net revenue fell to $275 million in 2025, down 16% year-over-year, indicating a decline in consumer interest in its plant-based meat products and resulting in severe financial challenges for the company.
- Product Launch: Beyond Meat launched its Beyond Immerse line of protein drinks in January 2026, and although the market is projected to reach $35 billion with a 9.4% CAGR through 2032, the product's limited-time offering has failed to boost investor confidence significantly.
- Deteriorating Financials: In Q1 2026, Beyond Meat reported net revenue of $58 million, a 15% year-over-year decline, and while losses improved from $61 million to $28 million, the company has yet to show signs of financial recovery, reflecting its vulnerable position in a competitive beverage market.
- Bleak Investment Outlook: Competing against industry giants like PepsiCo and Coca-Cola, Beyond Meat's protein drinks have not proven to be the turnaround catalyst needed for its stock, leading investors to approach the stock with caution unless the products gain traction and demonstrate sales growth.
See More
